SIR 2024
Interventional Oncology
Muhammad Shamim, BS
Interventional Radiologist
Baylor College of Medicine
Disclosure information not submitted.
Arsallan Nisar, MHS (he/him/his)
Medical student
EnMED A&M
Financial relationships: Full list of relationships is listed on the CME information page.
Hunaid Rana, MD
Interventional Radiology Fellow
University of Texas Health Science Center
Disclosure information not submitted.
Juri Bassuner, MD
Assistant Professor
UT Health Science Center at Houston
Financial relationships: Full list of relationships is listed on the CME information page.
To review, discuss and describe the status of Cryoablation in the treatment of breast cancer. The effectiveness of cryogenic ablation for breast cancer is illustrated in the case of a 76-year-old female who had recurrent papillary carcinoma (ER+, PR+, Erb-B2 -) despite prior mastectomy and lumpectomy. Cryoablation was used to treat the mass, and subsequent mammograms revealed no residual tumor. Further research is needed to better characterize techniques in the utilization of cryoablation for breast cancer management. . For instance, incorporating functional FDG-PET/CT imaging can enhance the localization of malignancies and improve cryoablative procedure efficacy. It is essential to address the various advantages of cryoablation to expand its applicability.
Background: Minimally invasive ablative techniques have emerged as a significant player in the comprehensive management of various oncological conditions, more recently extending to breast cancer. Among these approaches, cryoablation has demonstrated efficacy in the control of neoplastic disease and alleviation of pain associated with malignancies. Cryoablation utilizes extremely cold temperatures to induce cell necrosis in malignant tissues by forming intracellular ice crystals, a sign of immediate cell death. It also enhances the immune system’s capacity to target and attack both local and distant neoplastic cells, exemplifying the abscopal effect. This abstract aims to provide an overview of the current and evolving role of cryoablation as a treatment modality for breast cancer.
Clinical Findings/Procedure Details: The American College of Surgeons Oncology Group achieved a 92% success rate in cryoablation of unifocal invasive ductal carcinoma less than 2 cm, and a 100% success rate for lesions smaller than 1 cm. Preliminary findings from the ICE3 clinical trial suggest a low recurrence rate of 2.06%. Additionally, in a study conducted by Littrup et al., multiple cryoablation probes were employed to treat tumors larger than 1 cm. This approach yielded exceptional outcomes, with all cases showing 100% negative biopsy margins and no instances of local recurrence during an 18-month follow-up period.
Conclusion and/or Teaching Points: